Literature DB >> 24038341

Therapeutic prospects for Parkinson disease.

C Warren Olanow1, Anthony H V Schapira.   

Abstract

Dopaminergic therapies such as levodopa have provided benefit for millions of patients with Parkinson's disease (PD) and revolutionized the treatment of this disorder. However patients continue to experience disability despite the best of modern treatment. Dopaminergic and surgical therapies are associated with potentially serious side effects. Non-motor and non-dopaminergic features such as freezing, falling, and dementia are not adequately controlled with available medications and represent the major source of disability for advanced patients. And, the disease continues to relentlessly progress. Major therapeutic unmet needs include a dopaminergic therapy that is not associated with serious side effects, a therapy that addresses the non-motor and non-dopaminergic features of the disease, and a disease-modifying therapy that slows or stops disease progression. This review will consider current attempts to address these issues and the obstacles that must be overcome in order to develop more effective therapies for PD.
Copyright © 2013 American Neurological Association.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24038341     DOI: 10.1002/ana.24011

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  43 in total

Review 1.  Therapeutic Potential of Baicalein in Alzheimer's Disease and Parkinson's Disease.

Authors:  Yanwei Li; Jinying Zhao; Christian Hölscher
Journal:  CNS Drugs       Date:  2017-08       Impact factor: 5.749

2.  CRISPR/Cas9 Editing of Glia Maturation Factor Regulates Mitochondrial Dynamics by Attenuation of the NRF2/HO-1 Dependent Ferritin Activation in Glial Cells.

Authors:  Govindhasamy Pushpavathi Selvakumar; Mohammad Ejaz Ahmed; Sudhanshu P Raikwar; Ramasamy Thangavel; Duraisamy Kempuraj; Iuliia Dubova; Daniyal Saeed; Haris Zahoor; Keerthivaas Premkumar; Smita Zaheer; Shankar Iyer; Asgar Zaheer
Journal:  J Neuroimmune Pharmacol       Date:  2019-02-27       Impact factor: 4.147

3.  Vitamin D Treatment Attenuates Neuroinflammation and Dopaminergic Neurodegeneration in an Animal Model of Parkinson's Disease, Shifting M1 to M2 Microglia Responses.

Authors:  Rosa Calvello; Antonia Cianciulli; Giuseppe Nicolardi; Francesco De Nuccio; Laura Giannotti; Rosaria Salvatore; Chiara Porro; Teresa Trotta; Maria Antonietta Panaro; Dario Domenico Lofrumento
Journal:  J Neuroimmune Pharmacol       Date:  2016-12-16       Impact factor: 4.147

4.  The α7 nicotinic receptor agonist ABT-107 protects against nigrostriatal damage in rats with unilateral 6-hydroxydopamine lesions.

Authors:  Tanuja Bordia; Matthew McGregor; Roger L Papke; Michael W Decker; J Michael McIntosh; Maryka Quik
Journal:  Exp Neurol       Date:  2014-09-28       Impact factor: 5.330

5.  Stronger Dopamine D1 Receptor-Mediated Neurotransmission in Dyskinesia.

Authors:  Daniel Farré; Ana Muñoz; Estefanía Moreno; Irene Reyes-Resina; Júlia Canet-Pons; Iria G Dopeso-Reyes; Alberto J Rico; Carme Lluís; Josefa Mallol; Gemma Navarro; Enric I Canela; Antonio Cortés; José L Labandeira-García; Vicent Casadó; José L Lanciego; Rafael Franco
Journal:  Mol Neurobiol       Date:  2014-10-26       Impact factor: 5.590

6.  Pharmacological profile of opicapone, a third-generation nitrocatechol catechol-O-methyl transferase inhibitor, in the rat.

Authors:  M J Bonifácio; L Torrão; A I Loureiro; P N Palma; L C Wright; P Soares-da-Silva
Journal:  Br J Pharmacol       Date:  2015-01-20       Impact factor: 8.739

Review 7.  Synaptic plasticity and levodopa-induced dyskinesia: electrophysiological and structural abnormalities.

Authors:  Barbara Picconi; Elvira De Leonibus; Paolo Calabresi
Journal:  J Neural Transm (Vienna)       Date:  2018-02-28       Impact factor: 3.575

Review 8.  Non-motor features of Parkinson disease.

Authors:  Anthony H V Schapira; K Ray Chaudhuri; Peter Jenner
Journal:  Nat Rev Neurosci       Date:  2017-06-08       Impact factor: 34.870

Review 9.  Parkinson's disease, aging and adult neurogenesis: Wnt/β-catenin signalling as the key to unlock the mystery of endogenous brain repair.

Authors:  Bianca Marchetti; Cataldo Tirolo; Francesca L'Episcopo; Salvatore Caniglia; Nunzio Testa; Jayden A Smith; Stefano Pluchino; Maria F Serapide
Journal:  Aging Cell       Date:  2020-02-12       Impact factor: 9.304

Review 10.  The ongoing pursuit of neuroprotective therapies in Parkinson disease.

Authors:  Dilan Athauda; Thomas Foltynie
Journal:  Nat Rev Neurol       Date:  2014-12-02       Impact factor: 42.937

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.